Shares of Catalent, Inc. (NYSE:CTLT - Get Free Report) have earned a consensus rating of "Hold" from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold recommendation. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $59.83.
A number of brokerages have weighed in on CTLT. Robert W. Baird reiterated a "neutral" rating and issued a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Barclays lifted their price target on shares of Catalent from $47.00 to $63.00 and gave the company an "equal weight" rating in a report on Friday, June 28th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $63.50 price objective on shares of Catalent in a research note on Thursday, July 11th. StockNews.com started coverage on shares of Catalent in a research note on Saturday. They issued a "hold" rating for the company. Finally, William Blair restated a "market perform" rating on shares of Catalent in a research report on Tuesday, September 3rd.
Get Our Latest Stock Report on Catalent
NYSE:CTLT opened at $60.45 on Friday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. The company has a 50-day moving average of $60.03 and a 200-day moving average of $57.65. Catalent has a 52 week low of $31.80 and a 52 week high of $61.20. The company has a market capitalization of $10.94 billion, a price-to-earnings ratio of -9.91, a PEG ratio of 2.14 and a beta of 1.15.
Catalent (NYSE:CTLT - Get Free Report) last announced its quarterly earnings results on Thursday, August 29th. The company reported $0.57 EPS for the quarter, topping analysts' consensus estimates of $0.44 by $0.13. The firm had revenue of $1.30 billion during the quarter, compared to analysts' expectations of $1.23 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. As a group, equities research analysts anticipate that Catalent will post 0.95 earnings per share for the current fiscal year.
In related news, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the sale, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares of the company's stock, valued at $2,177,150.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Alessandro Maselli sold 9,088 shares of the stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the transaction, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,410 shares of company stock worth $732,680. Insiders own 0.31% of the company's stock.
Hedge funds have recently modified their holdings of the company. Gamco Investors INC. ET AL raised its position in Catalent by 403.3% in the 1st quarter. Gamco Investors INC. ET AL now owns 25,300 shares of the company's stock valued at $1,428,000 after buying an additional 20,273 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Catalent by 2,792.9% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company's stock valued at $29,150,000 after purchasing an additional 498,540 shares during the last quarter. UniSuper Management Pty Ltd grew its stake in Catalent by 509.4% in the first quarter. UniSuper Management Pty Ltd now owns 18,204 shares of the company's stock valued at $1,028,000 after purchasing an additional 15,217 shares in the last quarter. Swedbank AB acquired a new position in shares of Catalent during the 1st quarter worth approximately $1,659,000. Finally, SG Americas Securities LLC raised its stake in shares of Catalent by 147.4% during the 1st quarter. SG Americas Securities LLC now owns 99,588 shares of the company's stock worth $5,622,000 after purchasing an additional 59,339 shares in the last quarter.
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Catalent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalent wasn't on the list.
While Catalent currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.